$VNDA

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (3m)

—

Win rate (3m)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Oct 21, 12:15 PM ET

$VNDAr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 3h ago31 prior · 63% at 3mo

10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.

VNDA is 52 days from a Dec 12 PDUFA in the historical runup window, with positive Phase 3 data in late September. Despite recent underperformance, the market has historically underpriced Vanda news; the stock sits at $4.04 with strong cash runway of 14 months.

At post $4.01Now $4.07+1.4% since postedas of Oct 21, 12:15 PM ET

original post →

$VNDAr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 44d ago31 prior · 63% at 3mo

“Watching”

10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.

Imsidolimab (IL-36R antibody) for generalized pustular psoriasis achieved 53% skin clearance by week 4 vs 13% placebo on single IV dose in NEJM-published GEMINI trial, with PDUFA Dec 12. $328M cap and $170M liquidity support potential third approval in twelve months, though low market sentiment reflects past pipeline disappointments rather than data weakness.

At post $5.33Now $4.07-23.7% since postedas of Oct 21, 12:15 PM ET

1d—

3d-5.4%

1w-3.4%

1m-14.4%

3m—

6m—

1y—

original post →

End of results.